title: An Update on Phosphate Binders: A Dietitian's Perspective.
abstract: Control of serum phosphorus (PO4) has been long recognized as a goal in the nutritional and medical management of the patients with chronic kidney disease. Phosphate-binding compounds were introduced in the 1970s for the treatment of hyperphosphatemia in patients on dialysis after it was observed that oral administration of aluminum hydroxide as an antacid also reduced serum PO4 levels. Forty years later, aluminum is very seldom used as a phosphate binder as many other safer compounds are now available. This article is a comprehensive review, geared to the renal dietitian, of the most common binder categories. It will discuss pharmacokinetics, side effects, initial and optimal doses, phosphate affinity, and controversies of use. It will also review two novel approaches to serum PO4 management in chronic kidney disease patients receiving dialysis and provide a new calculation by which binders can be compared.
authors.affiliation: Davita, Inc., Denver, CO, Keryx Biopharmaceuticals, New York, New York. Electronic address: lgutekunstrd@gmail.com.
authors.forename: Lisa
authors.initials: L
authors.lastname: Gutekunst
mesh_terms: D000536:Aluminum Hydroxide / Q000494:pharmacology; D002119:Calcium Carbonate / Q000494:pharmacology; D004032:Diet; D004305:Dose-Response Relationship, Drug; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000188:drug therapy*; D007811:Lanthanum / Q000494:pharmacology; D064686:Nutritionists; D010710:Phosphates / Q000097:blood*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000188:drug therapy
chemical_list: D010710:Phosphates; D000536:Aluminum Hydroxide; D007811:Lanthanum; D002119:Calcium Carbonate